𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Present status of32P-therapy in management of polycythemia vera

✍ Scribed by Meuret, G.

Publisher
Springer-Verlag
Year
1975
Tongue
English
Weight
464 KB
Volume
53
Category
Article
ISSN
1432-1440

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Gain of 9p in the pathogenesis of polycy
Gain of 9p in the pathogenesis of polycythemia vera
✍ Zhong Chen; Mathilda Notohamiprodjo; Xin-Yuan Guan; Elisabeth Paietta; Sheryn Bl πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 190 KB πŸ‘ 1 views

Polycythemia vera (PV) is a clonal stem cell disorder characterized by excessive erythrocyte production, resulting in absolute erythrocytosis. No specific structural chromosomal abnormalities have been reported in PV to date. We have observed two cases of PV with an extra i(9)(p10) as the sole anoma

Leukemogenic risk of hydroxyurea therapy
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
✍ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 417 KB πŸ‘ 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a